Search Result
Results for "
cholesterol synthesis
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
10
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W020033
-
|
Endogenous Metabolite
|
Neurological Disease
|
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .
|
-
-
- HY-N3925
-
|
Bacterial
|
Infection
Metabolic Disease
Inflammation/Immunology
|
Ganoderol A is a terpenoid extracted from Ganoderma lucidum with antimicrobial activities. Ganoderol A inhibits cholesterol synthesis pathway and has significant anti-inflammatory activity and protection against ultraviolet A (UVA) damage .
|
-
-
- HY-125713
-
|
Glycosidase
Enterovirus
|
Infection
|
Ganoderic acid Y is a α-glucosidase inhibitor with an IC50 of 170 μM for yeast α-glucosidase. Ganoderic acid Y inhibits enterovirus 71 (EV71) replication through blocking EV71 uncoating .
|
-
-
- HY-W020033S
-
-
-
- HY-156197
-
-
-
- HY-124265
-
|
Endogenous Metabolite
|
Metabolic Disease
|
4β-hydroxy Cholesterol is a major oxysterol cholesterol metabolite and a precursor in the synthesis of bile acids that is found in human circulation .
|
-
-
- HY-17502
-
-
-
- HY-W020033R
-
|
Endogenous Metabolite
|
Neurological Disease
|
Lanosterol (Standard) is the analytical standard of Lanosterol. This product is intended for research and analytical applications. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases[1][2].
|
-
-
- HY-169321
-
-
-
- HY-167016
-
|
Liposome
|
Others
|
Cholesterol-undecanoate-glucose conjugate is a cholesterol conjugate used in the synthesis of intranasal liposomal vaccines. Cholesterol-undecanoate-glucose conjugate can be used in drug delivery studies .
|
-
-
- HY-N2221
-
-
-
- HY-121795
-
|
HMG-CoA Reductase (HMGCR)
|
Cardiovascular Disease
|
Pravastatin lactone is a potent HMG-CoA inhibitor. Pravastatin Lactone is a metabolite of pravastatin. Pravastatin lactone reduces blood cholesterol levels by inhibiting cholesterol synthesis .
|
-
-
- HY-16166
-
-
-
- HY-125666
-
|
Fungal
|
Infection
|
Agistatin B, isolated from fungus, is a mycotoxin. Agistatin B inhibits cholesterol synthesis .
|
-
-
- HY-113486S
-
-
-
- HY-121413
-
|
Endogenous Metabolite
|
Others
|
Clinolamide is an N-cyclohexyl linoleamide. In a rat cholesterol metabolism study, feeding it at a dose of 0.3% for 21 days had no significant effect on serum, liver or kidney cholesterol levels, but had different effects on cholesterol synthesis in liver slices under different substrates and concentrations.
|
-
-
- HY-114294A
-
HMG-CoA disodium hydrate
|
Biochemical Assay Reagents
|
Metabolic Disease
|
DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium hydrate is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor .
|
-
-
- HY-167936
-
|
Liposome
|
Neurological Disease
|
cis-AY 9944 is a cholesterol synthesis inhibitor, exhibiting anticonvulsant activity that influences the dynamics of spike and wave discharges in EEG recordings.
|
-
-
- HY-129098
-
DMHCA
1 Publications Verification
|
LXR
|
Metabolic Disease
|
DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects?and can be used for the research of cholesterol homeostasis diabetes .
|
-
-
- HY-104081
-
Cholestyramine resin; Colestyramine
|
Others
|
Cardiovascular Disease
Cancer
|
Cholestyramine (Colestyramine) is a bile acid binding resin and can inhibit intestinal bile acid absorption which results in the increasing bile acid synthesis from cholesterol.
|
-
-
- HY-124265S2
-
|
Endogenous Metabolite
|
Metabolic Disease
|
4β-Hydroxycholesterol-d4 is the deuterium labeled 4β-Hydroxycholesterol. 4β-hydroxy Cholesterol is a major oxysterol cholesterol metabolite and a precursor in the synthesis of bile acids that is found in human circulation .
|
-
-
- HY-N15411
-
|
Acyltransferase
Phytohormone
|
Metabolic Disease
|
Helminthosporol is a natural plant growth-regulator that can promote the growth of rice and lettuce seedlings. Helminthosporol can also inhibit the activity of acyl-CoA: cholesterol acyltransferase (ACAT) in rat liver microsomes and the synthesis of cholesterol esters in macrophages .
|
-
-
- HY-113342
-
|
Endogenous Metabolite
p38 MAPK
|
Cardiovascular Disease
Metabolic Disease
|
7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .
|
-
-
- HY-N0686
-
-
-
- HY-N1214
-
-
-
- HY-113037C
-
Farnesyl diphosphate ammonium
|
TRP Channel
Endogenous Metabolite
|
Neurological Disease
|
Farnesyl pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .
|
-
-
- HY-124265S1
-
-
-
- HY-106539
-
|
LDLR
|
Metabolic Disease
Cancer
|
Colesevelam (hydrochloride) is a bile acid sequestrant that bind bile acids in the gut. Colesevelam (hydrochloride) inhibits bile acid reabsorption, leading to increased bile acid synthesis and reduced cholesterol levels in patients with cholestatic pruritus and Crohn’s disease.
|
-
-
- HY-123349
-
|
Drug Metabolite
|
Cardiovascular Disease
|
5α-Hydroxy-6-keto cholesterol is major metabolite of β-epoxide (5α,6β-epoxycholesterol) during direct exposure of intact cultured human bronchial epithelial cells (16-HBE) to ozone. 5α-Hydroxy-6-keto cholesterol inhibits cholesterol synthesis with an IC50 of 350 nM .
|
-
-
- HY-113037
-
(E/Z)-Farnesyl diphosphate
|
TRP Channel
Endogenous Metabolite
|
Neurological Disease
|
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .
|
-
-
- HY-P5282
-
|
Acyltransferase
|
Others
|
ApoA-I mimetic peptide (PVLDLFRELLNELLEALKQKLK) has good lecithin:cholesterol acyl transferase (LCAT) activation potency. ApoA-I mimetic peptide can be used for synthesis of peptide/lipid complex .
|
-
-
- HY-B0144AS1
-
NK-104-d5 sodium
|
Apoptosis
HMG-CoA Reductase (HMGCR)
Mitophagy
Autophagy
|
Metabolic Disease
Cancer
|
Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
|
-
-
- HY-163452
-
|
Farnesyl Transferase
|
Metabolic Disease
|
Squalene synthase-IN-2 (comppund isomer A-(1S, 3R)-14i) is an orally active squalene synthase inhibitor with IC50 values of 3.4, 99 nM for squalene synthase and cholesterol synthesis, respectively. Squalene synthase-IN-2 reduces plasma cholesterol and triglyceride .
|
-
-
- HY-N1214S
-
Super Squalene-d6; trans-Squalene-d6; AddaVax-d6
|
Isotope-Labeled Compounds
|
Others
|
Squalene-d6 is a deuterium labeled Squalene. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-137089
-
20.25-Diazacholesterol dihydrochloride
|
CETP
|
Endocrinology
|
Azacosterol (SC-12937) dihydrochloride is a chemosterilant which in-hibits reproduction in the pigeon. Azacosterol (SC-12937) dihydrochloride exerts its inhibitory effect through the blocking of the synthesis of cholesterol, thought to be a vital component in the formation of egg yolks .
|
-
-
- HY-135383B
-
|
HMG-CoA Reductase (HMGCR)
|
Metabolic Disease
|
(Z)-Pitavastatin calcium is the Z-Isomer of Pitavastatin hemicacium. Pitavastatin calcium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin calcium inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells .
|
-
-
- HY-N0686R
-
|
Fatty Acid Synthase (FASN)
MicroRNA
|
Metabolic Disease
|
Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .
|
-
-
- HY-N1214R
-
|
Endogenous Metabolite
Reactive Oxygen Species
Fungal
|
Infection
Cardiovascular Disease
|
Squalene (Standard) is the analytical standard of Squalene. This product is intended for research and analytical applications. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-W749520
-
|
Dihydrofolate reductase (DHFR)
|
Metabolic Disease
|
Zymosterone is converted into zymosterol, an intermediate in cholesterol synthesis, through the action of the enzyme hydroxysteroid (17β) dehydrogenase 7 (HSD17B7), and this transformation, catalyzed by 3-keto sterol reductase (ERG27), plays a crucial role in the biosynthesis of ergosterol in yeast.
|
-
-
- HY-B0144A
-
NK-104
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
-
- HY-B0144B
-
NK-104 sodium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
-
- HY-W782762
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Dihydro FF-MAS is a steroid triterpenoid compound. Dihydro FF-MAS is an intermediate in the cholesterol synthesis pathway. Dihydro FF-MAS triggers the resumption of meiosis in cultured mouse oocytes in vitro, but not in vivo. Dihydro FF-MAS can be used in studies of reproduction and lipid metabolism .
|
-
-
- HY-16620
-
|
Endogenous Metabolite
|
Metabolic Disease
|
DF 461 is a sterol synthase inhibitor with significant inhibitory activity. DF 461 shows high selectivity for the liver and can effectively inhibit cholesterol synthesis in rat liver. DF 461 has shown the effect of lowering plasma lipids in repeated dosing studies in non-rodents .
|
-
-
- HY-B0144S
-
NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium
|
Isotope-Labeled Compounds
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Metabolic Disease
Cancer
|
Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
|
-
-
- HY-113000
-
|
Endogenous Metabolite
|
Cardiovascular Disease
|
Cetoleic acid is a long-chain monounsaturated fatty acid found in deep-sea fish. Cetoleic acid can promote the synthesis of ALA in human HepG2 cells and EPA in vitro in salmon liver cells, affecting cholesterol levels in rodents. Cetoleic acid has potential applications in cardiovascular disease research .
|
-
-
- HY-N7392
-
3-Oxobutanoyl-coenzyme A
|
Biochemical Assay Reagents
|
Metabolic Disease
|
Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids .
|
-
-
- HY-B0144
-
NK-104 hemicalcium; Pitavastatin hemicalcium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
-
- HY-N9220
-
|
Influenza Virus
|
Infection
|
6-Epi-albassitriol can be isolated from Aspergillus sp. FH-A 6357. 6-Epi-albassitriol inhibits the cholesterol synthesis with an inhibition rate of 40% at a concentration of 10 nM in HepG2. 6-Epi-albassitriol exhibits antiviral activity against influenza A virus and parainfluenza virus with MIC of 44.4-133.3 µg/mL .
|
-
-
- HY-B0144R
-
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Pitavastatin (Calcium) (Standard) is the analytical standard of Pitavastatin (Calcium). This product is intended for research and analytical applications. Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
-
- HY-N7264
-
-
- HY-113202
-
|
Endogenous Metabolite
PKC
GlyT
|
Neurological Disease
Metabolic Disease
|
Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .
|
-
- HY-W587530
-
6-Ketolithocholic acid
|
Endogenous Metabolite
Apoptosis
|
Endocrinology
|
6-Oxolithocholic acid is a bile acid metabolite derived from Lithocholic acid (HY-B0172). 6-Oxolithocholic acid has high cytotoxicity and can induce apoptosis, especially in hepatocytes. 6-Oxolithocholic acid can participate in the regulation of bile acid metabolism and synthesis and affect the metabolic pathway of cholesterol. 6-Oxolithocholic acid can be used to study the role of bile acids in health and disease, especially in the context of digestive and liver diseases .
|
-
- HY-111355B
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholesteryl sulfate sodium is an orally available, NPC2-targeted cholesterol biosynthesis agonist. Cholesteryl sulfate sodium activates SREBP2 by competitively binding to NPC2, promoting cholesterol synthesis (EC50=50 μM). Cholesteryl sulfate sodium enhances the self-assembly ability of Mitoxantrone hydrochloride (HY-13502A), while repairing the intestinal mucosal barrier and inhibiting inflammation by regulating serine protease activity and PKCη signaling pathway. Cholesteryl sulfate sodium is a component of the platelet cell membrane and supports platelet adhesion. Cholesteryl sulfate sodium also regulates the activity of selective protein kinase C isoforms and modulates the specificity of PI3K, playing a role in keratinocyte differentiation .
|
-
- HY-150407
-
|
Ligands for Target Protein for PROTAC
Autophagy
|
Others
Neurological Disease
Cancer
|
TSPO ligand-1 is the ligand of AUTAC4 (HY-134640) that can be used in the synthesis of PROTACs. TSPO ligand-1 is a mitochondrial outer membrane transmembrane structural domain protein can bind to AUTAC4 and regulate mitochondrial autophagy to promote targeted mitochondrial renewal. TSPO ligand-1 is also involved in the transport of cholesterol from the outer to inner mitochondrial membrane and serves as a sensitive biomarker of brain injury and neurodegeneration .
|
-
- HY-113202S
-
|
Isotope-Labeled Compounds
Endogenous Metabolite
PKC
GlyT
|
Neurological Disease
Metabolic Disease
|
Stearoyl-L-carnitine-d3 is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .
|
-
- HY-113081R
-
|
Endogenous Metabolite
PPAR
Hedgehog
|
Cancer
|
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .
In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells .
|
-
- HY-19671
-
SR-45023A; SR 9223i; SK&F-99085
|
Apoptosis
|
Cancer
|
Apomine (SR-45023A) is an antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis.
Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. In addition, Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .
|
-
- HY-23212A
-
|
Amino Acid Derivatives
|
Cancer
|
2-Amino-1,3-bis(carboxylethoxy)propane hydrochloride is a non-protein amino acid, sulfamic acid.2-Amino-1,3-bis(carboxylethoxy)propane hydrochloride contains one amino group and two terminal carboxylic acids.2-Amino-1,3-bis(carboxylethoxy)propane hydrochloride has a variety of physiological functions, including maintaining the stability of cell membranes, regulating cholesterol metabolism, supporting the normal function of the nervous system, participating in collagen synthesis, and anti-oxidation .
|
-
- HY-113202S1
-
|
Isotope-Labeled Compounds
GlyT
Endogenous Metabolite
PKC
|
Neurological Disease
Metabolic Disease
|
Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride, a fatty ester lipid molecule, is an endogenous metabolite. Stearoyl-L-carnitine chloride can be used as PKC inhibitor. Stearoyl-L-carnitine chloride accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoyl-L-carnitine chloride inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoyl-L-carnitine chloride acts as a metabolomics biomarker for Parkinson’s disease. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .
|
-
- HY-117219
-
|
Cytochrome P450
HMG-CoA Reductase (HMGCR)
Endogenous Metabolite
|
Metabolic Disease
|
SKF 104976 is a 3,2-carboxylic acid derivative with potent 14-alpha-demethylase (14 alpha DM) inhibitory activity. SKF 104976 inhibited 14 alpha DM activity by 50% at 2 nM in Hep G2 cell extracts. SKF 104976 inhibited the incorporation of [14C]acetate into cholesterol in intact cells at similar concentrations, accompanied by accumulation of lanosterol, and resulted in a 40-70% decrease in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) activity. SKF 104976 did not affect the uptake and degradation of low-density lipoprotein in Hep G2 cells, indicating that HMGR and low-density lipoprotein receptor activities are not coordinately regulated under these conditions. The inhibitory effect of SKF 104976 on HMGR activity remained unchanged even when the flux of carbon units in the sterol synthesis pathway was reduced by 80%. SKF 104976 did not inhibit HMGR activity under conditions where sterol synthesis was almost completely blocked by lovastatin .
|
-
- HY-113259
-
|
Endogenous Metabolite
|
Metabolic Disease
|
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
|
-
- HY-W015600
-
Orthocetamol
|
Ferroptosis
Glutathione Peroxidase
Reactive Oxygen Species
LDLR
|
Cardiovascular Disease
Inflammation/Immunology
|
2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe 2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .
|
-
- HY-113259S
-
|
Endogenous Metabolite
|
Metabolic Disease
|
7α-Hydroxy-4-cholesten-3-one-d7 is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
|
-
- HY-W015600R
-
Orthocetamol (Standard)
|
Ferroptosis
Glutathione Peroxidase
Reactive Oxygen Species
LDLR
|
Cardiovascular Disease
Inflammation/Immunology
|
2-Acetamidophenol (Standard) is the analytical standard of 2-Acetamidophenol. This product is intended for research and analytical applications. 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe 2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .
|
-
- HY-113259R
-
|
Endogenous Metabolite
|
Metabolic Disease
|
7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-114294A
-
HMG-CoA disodium hydrate
|
Enzyme Substrates
|
DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium hydrate is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor .
|
-
- HY-P5282
-
|
Drug Delivery
|
ApoA-I mimetic peptide (PVLDLFRELLNELLEALKQKLK) has good lecithin:cholesterol acyl transferase (LCAT) activation potency. ApoA-I mimetic peptide can be used for synthesis of peptide/lipid complex .
|
-
- HY-167016
-
|
Drug Delivery
|
Cholesterol-undecanoate-glucose conjugate is a cholesterol conjugate used in the synthesis of intranasal liposomal vaccines. Cholesterol-undecanoate-glucose conjugate can be used in drug delivery studies .
|
-
- HY-N7392
-
3-Oxobutanoyl-coenzyme A
|
Biochemical Assay Reagents
|
Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P5282
-
|
Acyltransferase
|
Others
|
ApoA-I mimetic peptide (PVLDLFRELLNELLEALKQKLK) has good lecithin:cholesterol acyl transferase (LCAT) activation potency. ApoA-I mimetic peptide can be used for synthesis of peptide/lipid complex .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W020033S
-
|
Lanosterol-d6 is deuterium labeled Lanosterol. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol s
|
-
-
- HY-113486S
-
|
(S)-Lathosterol-d4 is the deuterium labeled (S)-Lathosterol. Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis .
|
-
-
- HY-124265S2
-
|
4β-Hydroxycholesterol-d4 is the deuterium labeled 4β-Hydroxycholesterol. 4β-hydroxy Cholesterol is a major oxysterol cholesterol metabolite and a precursor in the synthesis of bile acids that is found in human circulation .
|
-
-
- HY-B0144AS1
-
|
Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
|
-
-
- HY-113259S
-
|
7α-Hydroxy-4-cholesten-3-one-d7 is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
|
-
-
- HY-124265S1
-
|
4β-Hydroxycholesterol-d5 is the deuterium labeled 4β-Hydroxycholesterol (HY-124265). 4β-hydroxy Cholesterol is a major oxysterol cholesterol metabolite and a precursor in the synthesis of bile acids that is found in human circulation .
|
-
-
- HY-N1214S
-
|
Squalene-d6 is a deuterium labeled Squalene. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-B0144S
-
|
Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
|
-
-
- HY-113202S
-
|
Stearoyl-L-carnitine-d3 is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .
|
-
-
- HY-113202S1
-
|
Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride, a fatty ester lipid molecule, is an endogenous metabolite. Stearoyl-L-carnitine chloride can be used as PKC inhibitor. Stearoyl-L-carnitine chloride accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoyl-L-carnitine chloride inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoyl-L-carnitine chloride acts as a metabolomics biomarker for Parkinson’s disease. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-156197
-
|
|
Cholesterol
|
Biotin-cholesterol is a biotinylated form of Cholesterol (HY-N0322). Biotin-cholesterol can be used in the synthesis of biotin-conjugated liposomes and micelles for drug delivery .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: